Human EAG channels are directly modulated by PIP2 as revealed by electrophysiological and optical interference
Bo Han1, Kunyan He1, Chunlin Cai1
1Key Laboratory of Systems Biomedicine (Ministry of Education), Institute of Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China.
Abstract:
Voltage-gated ether à go-go (EAG) K(+) channels are expressed in various types of cancer cells and also in the central nervous system. Aberrant overactivation of human EAG1 (hEAG1) channels is associated with cancer and neuronal disorders such as Zimmermann-Laband and Temple-Baraitser syndromes. Although hEAG1 channels are recognized as potential therapeutic targets, regulation of their functional properties is only poorly understood. Here, we show that the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) is a potent inhibitory gating modifier of hEAG1 channels. PIP2 inhibits the channel activity by directly binding to a short N-terminal segment of the channel important for Ca(2+)/calmodulin (CaM) binding as evidenced by bio-layer interferometry measurements. Conversely, depletion of endogenous PIP2 either by serotonin-induced phospholipase C (PLC) activation or by a rapamycin-induced translocation system enhances the channel activity at physiological membrane potentials, suggesting that PIP2 exerts a tonic inhibitory influence. Our study, combining electrophysiological and direct binding assays, demonstrates that hEAG1 channels are subject to potent inhibitory modulation by multiple phospholipids and suggests that manipulations of the PIP2 signaling pathway may represent a strategy to treat hEAG1 channel-associated diseases.
Insights
Phosphatidylinositol 4,5-bisphosphate (PIP2) inhibits human ether-à-go-go 1 (hEAG1) potassium channels by direct binding. Modulating PIP2 levels affects hEAG1 channel activity, offering potential therapeutic strategies for associated diseases.
Area of Science:
- Molecular Biology
- Neuroscience
- Biochemistry
Background:
- Voltage-gated potassium channels, specifically human ether-à-go-go 1 (hEAG1), are implicated in cancer and neurological disorders.
- Aberrant hEAG1 channel activity is linked to diseases like Zimmermann-Laband and Temple-Baraitser syndromes.
- Understanding the regulation of hEAG1 channel function is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) in modulating hEAG1 channel activity.
- To elucidate the molecular mechanism by which PIP2 interacts with and regulates hEAG1 channels.
- To explore the therapeutic potential of targeting the PIP2 signaling pathway for hEAG1-associated diseases.
Main Methods:
- Electrophysiological recordings to assess hEAG1 channel function.
- Bio-layer interferometry to directly measure PIP2 binding to hEAG1 channel segments.
- Pharmacological manipulation of endogenous PIP2 levels using serotonin-induced phospholipase C (PLC) activation and rapamycin-induced translocation systems.
Main Results:
- Phosphatidylinositol 4,5-bisphosphate (PIP2) acts as a potent inhibitor of hEAG1 channel activity.
- PIP2 directly binds to a specific N-terminal segment of the hEAG1 channel, which is also involved in Ca(2+)/calmodulin binding.
- Depletion of endogenous PIP2 enhances hEAG1 channel activity at physiological membrane potentials, indicating a tonic inhibitory role for PIP2.
- hEAG1 channels are modulated by multiple phospholipids, suggesting broad regulatory mechanisms.
Conclusions:
- PIP2 is a critical regulator of hEAG1 channel gating, acting through direct physical interaction.
- The findings reveal a novel mechanism for controlling hEAG1 channel function relevant to both cancer and neurological disorders.
- Targeting the PIP2 signaling pathway presents a promising therapeutic strategy for diseases associated with hEAG1 channel dysfunction.
Related Concept Videos
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
IP3/DAG Signaling Pathway
Amplifying Signals via Second Messengers
Hedgehog Signaling Pathway


